Life Science Series: Risks for multinational pharmaceuticals in India episode artwork

EPISODE · Sep 6, 2024 · 13 MIN

Life Science Series: Risks for multinational pharmaceuticals in India

from Control Risks · host Control Risks

India is an important market for many multinational pharmaceutical, biotech or medical device companies. But it is also a challenging one. Join Martina Rozumberkova for a conversation with Sushmit Bhattacharya about challenges facing multinational pharmaceutical companies operating in India, from important regulatory changes, including the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) 2024, to emerging fraud schemes, including fraud in the Government e-Marketplace (GeM) and retailer incentive schemes.

Episode metadata supplied by the publisher feed · Published Sep 6, 2024

Embed this episode

NOW PLAYING

Life Science Series: Risks for multinational pharmaceuticals in India

0:00 13:25

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Control Risks?

This episode is 13 minutes long.

When was this Control Risks episode published?

This episode was published on September 6, 2024.

Can I download this Control Risks episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!